{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:52Z","timestamp":1792096972474,"version":"4.4.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In recent years, many guidelines related to aspergillosis have been published worldwide. However, no studies have applied assessment tools to systematically evaluate the quality of these guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to assess the quality of clinical practice guidelines and compared their recommendations related to drug therapy for the prevention and treatment of invasive aspergillosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic databases, guideline development organizations, and professional society websites were searched to identify clinical practice guidelines for invasive aspergillosis published between 1 January 2013, and 12 September 2023. The Appraisal of Guidelines Research and Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Recommendations for the drug prevention and treatment of invasive aspergillosis were extracted and descriptively analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 18 included clinical practice guidelines, the median scores and interquartile range for each AGREE II domain were: scope and purpose, 76.39% (69.1%, 80.21%); stakeholder involvement, 59.72% (50.35%, 67.02%); rigor of development, 64.58% (44.4%, 72.27%); clarity and presentation, 81.25% (68.06%, 91.32%); applicability, 41.67% (36.46%, 47.92%); and editorial independence, 76.05% (50%, 87.5%). Voriconazole and isavuconazole are recommended as first-line therapy for invasive aspergillosis currently. Posaconazole remains the first choice for invasive aspergillosis prophylaxis in patients with hematological malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The development processes and reporting of invasive aspergillosis -related clinical practice guidelines varied and their quality requires improvement. The guideline recommendations have changed since the approval of isavuconazole.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1443487","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:03:03Z","timestamp":1743400983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Appraisal of guidelines and variations in recommendations on drug therapy for invasive aspergillosis prevention and treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jiph.2013.08.003","article-title":"Clinical practice guidelines for the treatment of invasive Aspergillus infections in adults in the Middle East region: expert panel recommendations","volume":"7","author":"Al-Abdely","year":"2014","journal-title":"J. Infect. Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/s2213-2600(20)30237-x","article-title":"Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19","volume":"8","author":"Alanio","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Cmaj"},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern Med. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood-2002-05-1356","article-title":"Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies","volume":"101","author":"Cornely","year":"2003","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American society of transplantation and cellular therapy series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/jof10030191","article-title":"A phase I\/IIa prospective, randomized, open-label study on the safety and efficacy of nebulized liposomal amphotericin for invasive pulmonary aspergillosis","volume":"10","author":"Fort\u00fan","year":"2024","journal-title":"J. Fungi (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enfermedades Infecc. Y Microbiol. Clin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20","author":"Gavald\u00e0","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2478\/ahp-2020-0014","article-title":"Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of polish society of hematology and Blood transfusion, polish society of pediatric oncology and hematology, and polish adult leukemia study group, 2020","volume":"51","author":"Gil","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B15","unstructured":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.pupt.2023.102233","article-title":"Safety and usefulness of nebulized liposomal amphotericin B: systematic scoping review","volume":"82","author":"Hagiya","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin. Transpl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jof2020015","article-title":"Aspergillosis in chronic granulomatous disease","volume":"2","author":"King","year":"2016","journal-title":"J. Fungi (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3314\/mmj.16-00010","article-title":"Executive summary of Japanese domestic guidelines for management of deep-seated mycosis 2014","volume":"57","author":"Kohno","year":"2016","journal-title":"Med. Mycol. J."},{"key":"B20","volume-title":"SWAB guidelines for the management of invasive fungal infections","author":"Kullberg","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmii.2017.07.006","article-title":"2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan","volume":"51","author":"Kung","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cid\/ciae501","article-title":"Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial","volume":"80","author":"Lamberink","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-024-09477-9","article-title":"Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/m13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1128\/aac.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.22354\/24223794.1064","article-title":"Section 2. Colombian consensus for prophylaxis, treatment and prevention of invasive aspergillosis in adult and pediatric patients","volume":"26","author":"O\u00f1ate","year":"2022","journal-title":"Infectio"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/myc.13082","article-title":"Treatment of invasive fungal diseases in cancer patients-revised 2019 recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO)","volume":"63","author":"Ruhnke","year":"2020","journal-title":"Mycoses"},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3760\/cma.j.issn.0254-1785.2016.05.09","article-title":"Chinese clinical guidelines for the diagnosis and treatment of invasive fungal diseases in 484 solid organ transplant recipients (2016 edition)","volume":"485","author":"Shi","year":"2016","journal-title":"Chin. J. Organ Transplant."},{"key":"B34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ajt.12115","article-title":"Aspergillosis in solid organ transplantation","volume":"13","author":"Singh","year":"2013","journal-title":"Am. J. Transpl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"B39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jmii.2022.12.003","article-title":"Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in Taiwan","volume":"56","author":"Wu","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1443487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:03:19Z","timestamp":1743400999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1443487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1443487"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1443487","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"article-number":"1443487"}}